Page 54 - Haematologica-5

C. Lagresle-Peyrou et al.
cell disease. N Engl J Med. 2017;376(9):
848-855.
5. Cavazzana M, Ribeil JA, Lagresle-Peyrou
C, Andre-Schmutz I. Gene therapy with hematopoietic stem cells: the diseased bone marrow's point of view. Stem Cells Dev. 2017;26(2):71-76.
6. Wang TF, Chen SH, Yang SH, Su YC, Chu SC, Li DK. Poor harvest of peripheral blood stem cell in donors with microcytic red blood cells. Transfusion. 2013;53 (1):91-95.
7. Constantinou VC, Bouinta A, Karponi G, et al. Poor stem cell harvest may not always be related to poor mobilization: lessons gained from a mobilization study in patients with beta-thalassemia major. Transfusion. 2017;57(4):1031-1039.
8. Abboud M, Laver J, Blau CA. Granulocytosis causing sickle-cell crisis. Lancet. 1998;351(9107):959.
9. Adler BK, Salzman DE, Carabasi MH, Vaughan WP, Reddy VV, Prchal JT. Fatal sickle cell crisis after granulocyte colony- stimulating factor administration. Blood. 2001;97(10):3313-3314.
10. Grigg AP. Granulocyte colony-stimulating factor-induced sickle cell crisis and multior- gan dysfunction in a patient with com- pound heterozygous sickle cell/beta+ tha- lassemia. Blood. 2001;97(12):3998-3999.
11. Onitilo AA, Lazarchick J, Brunson CY, Frei- Lahr D, Stuart RK. Autologous bone mar- row transplant in a patient with sickle cell disease and diffuse large B-cell lymphoma. Transplant Proc. 2003;35(8):3089-3092.
12. Kamble RT, Tin UC, Carrum G. Successful mobilization and transplantation of filgras- tim mobilized hematopoietic stem cells in sickle cell-hemoglobin C disease. Bone Marrow Transplant. 2006;37(11):1065- 1066.
13. Rosenbaum C, Peace D, Rich E, Van Besien K. Granulocyte colony-stimulating factor- based stem cell mobilization in patients with sickle cell disease. Biol Blood Marrow Transplant. 2008;14(6):719-723.
14. Tormey CA, Snyder EL, Cooper DL. Mobilization, collection, and transplanta- tion of peripheral blood hematopoietic pro- genitor cells in a patient with multiple myeloma and hemoglobin SC disease. Transfusion. 2008;48(9):1930-1933.
15. Liles WC, Broxmeyer HE, Rodger E, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a
CXCR4 antagonist. Blood. 2003;102(8): moratorium? Cytotherapy. 2009;11(4):464-
2728-2730. 471.
16. Schroeder MA, Rettig MP, Lopez S, et al. 27. Yannaki E, Papayannopoulou T, Jonlin E, et
Mobilization of allogeneic peripheral blood al. Hematopoietic stem cell mobilization stem cell donors with intravenous plerix- for gene therapy of adult patients with afor mobilizes a unique graft. Blood. severe beta-thalassemia: results of clinical 2017;129(19):2680-2692. trials using G-CSF or plerixafor in splenec-
17. Broxmeyer HE, Orschell CM, Clapp DW, et tomized and nonsplenectomized subjects. al. Rapid mobilization of murine and Mol Ther. 2012;20(1):230-238.
human hematopoietic stem and progenitor 28. Richard RE, Siritanaratkul N, Jonlin E, cells with AMD3100, a CXCR4 antagonist. Skarpidi E, Heimfeld S, Blau CA. Collection J Exp Med. 2005;201(8):1307-1318. of blood stem cells from patients with sick-
18. Devine SM, Flomenberg N, Vesole DH, et le cell anemia. Blood Cells Mol Dis. al. Rapid mobilization of CD34+ cells fol- 2005;35(3):384-388.
lowing administration of the CXCR4 29. Charache S, Terrin ML, Moore RD, et al. antagonist AMD3100 to patients with mul- Effect of hydroxyurea on the frequency of tiple myeloma and non-Hodgkin's lym- painful crises in sickle cell anemia. phoma. J Clin Oncol. 2004;22(6):1095- Investigators of the Multicenter Study of 1102. Hydroxyurea in Sickle Cell Anemia. N Engl
19. Karponi G, Psatha N, Lederer CW, et al. J Med. 1995;332(20):1317-1322. Plerixafor+G-CSF-mobilized CD34+ cells 30. Alvarez-Larran A, Perez-Encinas M, Ferrer- represent an optimal graft source for tha- Marin F, et al. Risk of thrombosis according lassemia gene therapy. Blood. 2015;126(5): to need of phlebotomies in patients with 616-619. polycythemia vera treated with hydrox-
20. Ferrari G, Cavazzana M, Mavilio F. Gene yurea. Haematologica. 2017;102(1):103- therapy approaches to hemoglobinopathies. 109.
Hematol Oncol Clin North Am. 2017;31(5): 31. Halter J, Kodera Y, Ispizua AU, et al. Severe 835-852. events in donors after allogeneic
21. Lionnet F, Arlet JB, Bartolucci P, et al. hematopoietic stem cell donation. [Guidelines for management of adult sickle Haematologica. 2009;94(1):94-101.
cell disease]. Rev Med Interne. 2009;30 32. Lack NA, Green B, Dale DC, et al. A phar- (Suppl 3):S162-223. macokinetic-pharmacodynamic model for
22. Lamming CE, Augustin L, Blackstad M, the mobilization of CD34+ hematopoietic Lund TC, Hebbel RP, Verfaillie CM. progenitor cells by AMD3100. Clin Spontaneous circulation of myeloid-lym- Pharmacol Ther. 2005;77(5):427-436. phoid-initiating cells and SCID-repopulat- 33. To LB, Levesque JP, Herbert KE. How I treat ing cells in sickle cell crisis. J Clin Invest. patients who mobilize hematopoietic stem 2003;111(6):811-819. cells poorly. Blood. 2011;118(17):4530-
23. Doulatov S, Notta F, Eppert K, Nguyen LT, 4540.
Ohashi PS, Dick JE. Revised map of the 34. Lefrere F, Mauge L, Rea D, et al. A specific human progenitor hierarchy shows the ori- time course for mobilization of peripheral gin of macrophages and dendritic cells in blood CD34+ cells after plerixafor injection early lymphoid development. Nat in very poor mobilizer patients: impact on Immunol. 2010;11(7):585-593. the timing of the apheresis procedure.
24. Six EM, Bonhomme D, Monteiro M, et al. Transfusion. 2013;53(3):564-569.
A human postnatal lymphoid progenitor 35. Pantin J, Purev E, Tian X, et al. Effect of capable of circulating and seeding the thy- high-dose plerixafor on CD34(+) cell mobi- mus. J Exp Med. 2007;204(13):3085-3093. lization in healthy stem cell donors: results
25. Handgretinger R, Kuci S. CD133-positive of a randomized crossover trial. hematopoietic stem cells: from biology to Haematologica. 2017;102(3):600-609. medicine. Adv Exp Med Biol. 2013;777:99- 36. Weisser M, Demel UM, Stein S, et al. 111. Hyperinflammation in patients with chron-
26. Fitzhugh CD, Hsieh MM, Bolan CD, Saenz ic granulomatous disease leads to impair- C, Tisdale JF. Granulocyte colony-stimulat- ment of hematopoietic stem cell functions. ing factor (G-CSF) administration in indi- J Allergy Clin Immunol. 2016;138(1):219- viduals with sickle cell disease: time for a 228.e219.
786
haematologica | 2018; 103(5)